


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.39%
+24.05%
+1.04%
-8.58%
+2.33%
OGN
Organon &
$6.63
Strengths

Earnings are forecast to grow

Investors confidence is positive
Risk Analysis

Downgraded on weak valued
Chart
$9.92 (-33.17%)
$9.36 (-29.17%)
$10.19 (-34.94%)
$14.59 (-54.56%)
OGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

OGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Downgraded on weak valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
OGN Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
OGN Street view is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is OGN current stock price?
What are OGN stock strengths?
What risks are associated with OGN stock?
When is OGN next earnings report?
What is OGN market cap and volume?
What is OGN's current Stock IQ?
Should I buy OGN stock right now?
Is OGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for OGN?
What does a 'Strong Sell' rating mean for OGN?
What factors influence OGN's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.39%
+24.05%
+1.04%
-8.58%
+2.33%
OGN
Organon &
Current Price
$6.63
Stock Insights
Strengths

Earnings are forecast to grow

Investors confidence is positive
Risk Analysis

Downgraded on weak valued

Chart
$9.92 (-33.17%)
$9.36 (-29.17%)
$10.19 (-34.94%)
$14.59 (-54.56%)
OGN Analysts Opinion
OGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Downgraded on weak valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
OGN Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
OGN Street view is unimpressive and have negative views on the near-term outlook
OGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Average key support and resistance price levels.
OGN Latest Analysis
Jim Cramers Worst Stock Ever Might Be Organon (OGN). We recently published 11 Stocks Jim Cramer Discussed Including A Potential Worst Stock Ever. Organon &. Co. (NYSE:OGN) is one of the stocks Jim Cramer recently discussed. Organon &. Co. (NYSE:OGN) is a womens health company that provides fertility and contraceptive products. Its been caught in a wave of controversy lately after CEO Kevin Ali [….]
Thu Oct 30, 2025
Organon: Critical Assessment Of The Audit Committee Investigation Results.
Wed Oct 29, 2025
The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products.
Tue Oct 28, 2025
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices Abrupt CEO Departure -- Hagens Berman. SAN FRANCISCO Oct. 27 2025 (GLOBE NEWSWIRE) -- On October 27 2025 investors in Organon &. Co. (Nexplanon and CEO Kevin Ali'.s resignation.The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Organon and its now-former CEO intentionally misled investors about the company'.s adhe
Mon Oct 27, 2025
Organon cut to Underweight at Piper Sandler on internal control concerns.
Mon Oct 27, 2025
Organon CEO Kevin Ali Resigns As Probe Finds Improper Wholesaler Sales Practices. Stock Down . (RTTNews) - Organon & Co. (OGN) a pharmaceutical company said on Monday that its Chief Executive Officer Kevin Ali has stepped down after an internal investigation found improper wholesaler sales practices for its Nexplanon product.
Mon Oct 27, 2025
Organon (OGN) Laps the Stock Market: Heres Why. The latest trading day saw Organon (OGN) settling at $9.05 representing a 1.23% change from its previous close.
Thu Oct 23, 2025
Organon (OGN) Earnings Expected to Grow: Should You Buy?. Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu Oct 23, 2025
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It. Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore it is wise to be aware of the facts that can impact the stocks prospects.
Tue Oct 21, 2025
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors. In the latest trading session Organon (OGN) closed at $9.28 marking a -1.07% move from the previous day.
Fri Oct 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.